The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
This article is relevant because of the concept of combining statins with other agents is going to become the norm for "next" generation lipid agents. The question is which combo will be doctors prescribe?
The article is accurate about addiction but ignores an important issue: the untreated pain in the world is bigger than the addiction issue. The Addiction issue is a political issue(in an election year no less) and the human side of pain is real and nobody is without pain. Pain is the 5th...
It appears from the breifing documents that the FDA has concerns about the CV safety of Avandia. They appear to be less concerned about the CV safety of Actos but both drugs are associated with an increase risk of heart failure. It is unknown how the Advisory Committee will vote but based on the available...
ExForge is a product that we in the hypertension business are very anxious to have available. Combination tablets have been increasing in sales very dramatically in the past few years and will soon overtake, in my opinion, single agents. Lotrel led the way toward combinations that do not include a diuretic...
Gee whiz, so Cephalon had isolated the enantiomer of provigil that is effetcive. This is the equivalent to AZ isoloating the s enantiomer of ompeprazole to create Nexium and lord ir over prilosec. This is no great feat chemically or pharmacologiclly. What it may mean is millions in profits for investors....
It is clear that the panel felt that there was inadequate data on the psychiatric implications of rimonabant. It is a strong statement coming in the wake of the rosiglitazone mess (with strong recollections of cerivastatin and Vioxx) demonstrating that the FDA will be very finicky about approvals in...
It is clear that the advisory panel is more concerned with safety in a limited population that the broader impact of obesity and its metabolic problems and acceleration of diabetes and atherosclerosis. This demonstrates the likelihood that the FDA will likely be posturing to reflect the rosiglitazone...